EAM Investors’s Insight Molecular Diagnostics IMDX Stock Holding History

EAM Investors’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,088	Closed	-$462K	–	332
2020 Q2	$462K	Buy	+12,088	New	+$624K	0.1%	252
2019 Q2	–	Sell	-8,482	Closed	-$670K	–	301
2019 Q1	$670K	Buy	+8,482	New	+$547K	0.16%	229

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

EAM Investors's IMDX Position: Q3 2020 in Review

EAM Investors sold out of Insight Molecular Diagnostics (IMDX) in Q3 2020, closing a stake of 12,088 shares — an estimated $462K sold.

EAM Investors first reported a position in IMDX in Q1 2019 and held it in 2 quarters. The position peaked at $670K in Q1 2019. 59 funds tracked by Wall St. Rank hold IMDX as of Q3 2020.

EAM Investors reported no remaining Insight Molecular Diagnostics position as of Q3 2020 after selling out during the quarter.
EAM Investors sold 12,088 Insight Molecular Diagnostics shares in Q3 2020, an estimated $462K.
EAM Investors first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 2 quarters.
EAM Investors's Insight Molecular Diagnostics position peaked at $670K in Q1 2019.
59 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.